Journal
MOLECULAR GENETICS AND METABOLISM REPORTS
Volume 33, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ymgmr.2022.100935
Keywords
Lysosomal acid lipase deficiency (LAL-D); Enzymatic activity; Dried blood spot (DBS); Newborn screening
Categories
Funding
- National Institutes of Health [R01 DK067859]
Ask authors/readers for more resources
The new enzymatic activity assay using a specific substrate provides an improved method for the diagnosis and prognosis of LAL-D patients, especially for asymptomatic individuals identified through newborn screening.
Background: Lysosomal acid lipase deficiency (LAL-D) is a phenotypic continuum between the severe Wolman disease and the attenuated cholesteryl ester storage disease (CESD).Objective: To study if the amount of residual LAL enzymatic activity in dried blood spots (DBS) correlates with the LAL-D disease severity. Methods: DBS from Wolman and CESD patients, LAL-D carriers, and presumably unaffected random newborns were acquired. LAL enzymatic activity in DBS were measured using a novel, highly specific LAL substrate.Results: Patients with Wolman disease displayed significantly lower LAL enzymatic activity compared to CESD patients. This was not observed with the traditional assay in which a non-specific substrate was used together with an LAL-specific inhibitor.Conclusion: The new LAL enzymatic activity assay using the specific substrate offers an improved biochemical genetics method for the diagnosis of LAL-D in symptomatic patients and more importantly, for the prognosis of asymptomatic patients who test positive in population-wide LAL-D newborn screening.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available